bpc 157 multiple sclerosis clinical trial humans BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Frontiers | New views on
Description
Celecoxibinduced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or Larginine, aggravation by LNAME
doi:10.3389/fendo.2020.00624
Blood (1996) 87:2095147
But it makes the screening non-negotiable
BPC-157 contains four proline residues, including an unusual triple-proline sequence
